DK1912640T3 - Anvendelse af hdac-hæmmeren panobinostat til behandling af myelom - Google Patents
Anvendelse af hdac-hæmmeren panobinostat til behandling af myelom Download PDFInfo
- Publication number
- DK1912640T3 DK1912640T3 DK06789025.1T DK06789025T DK1912640T3 DK 1912640 T3 DK1912640 T3 DK 1912640T3 DK 06789025 T DK06789025 T DK 06789025T DK 1912640 T3 DK1912640 T3 DK 1912640T3
- Authority
- DK
- Denmark
- Prior art keywords
- myeloma
- combination
- hdac inhibitor
- cells
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
- ANVENDELSE AF HDAC-HÆMMEREN PANOBINOSTAT TIL BEHANDLING AF MYELOM PATENTKRAV1. Anvendelse af en HDAC-hæmmer til fremstilling af et medikament til behandling af myelom, hvor HDAC-hæmmeren er V-hydroxy-3-[4-[[[2-(2-methyl-l//-indol-3-yl)-cthyl]-amino]mcthyl]phcnyl]-2L'-2-propenamid med formlen (III)(Hl) > eller et farmaceutisk acceptabelt salt deraf, og hvor myelomet er resistent over for traditionel kemoterapi.
- 2. Anvendelse ifølge krav 1, hvor sygdommen er multipelt myelom.
- 3. HDAC-inhibitor, der er A-hydroxy-3-[4-[[[2-(2-methyl-l//-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2£'-2-propenamid med formlen (III)(III) i eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandlingen af myelom, hvor myelomet er resistent over for traditionel kemoterapi.
- 4. HDAC-hæmmer ifølge krav 3 til anvendelse ifølge krav 3, hvor sygdommen er multipelt myelom.
- 5. Kombination til anvendelse i behandlingen af myelom, hvilken kombination omfatter en HDAC-hæmmer og en forbindelse, der bevirker apoptose af myelomceller, hvori de aktive bestanddele er til stede i hvert tilfælde i fri form eller i form af et farmaceutisk acceptabelt salt og eventuelt mindst én farmaceutisk acceptabel bærer, hvor HD AC-hæmmeren er V-hydroxy-3-[4-[[[2-(2-methyl-lF/-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2ii-2-propenamid med formlen (III)(III) * og hvor forbindelsen, der bevirker apoptose af myelomceller, er bortezomib.
- 6. Kombination ifølge krav 5 til anvendelse ifølge krav 5, hvor anvendelsen er en simultan, separat eller sekventiel anvendelse.
- 7. Kombination ifølge krav 5 til anvendelse ifølge krav 5 eller 6, hvor myelomet er multipelt myelom.
- 8. Farmaceutisk sammensætning omfattende en kvantitet, der sammen er terapeutisk effektiv mod myelom, af en kombination ifølge krav 5 og mindst én farmaceutisk acceptabel bærer, til anvendelse i behandlingen af myelom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70522605P | 2005-08-03 | 2005-08-03 | |
| PCT/US2006/029801 WO2007019116A1 (en) | 2005-08-03 | 2006-08-01 | Use of hdac inhibitors for the treatment of myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1912640T3 true DK1912640T3 (da) | 2015-09-14 |
Family
ID=37307336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06789025.1T DK1912640T3 (da) | 2005-08-03 | 2006-08-01 | Anvendelse af hdac-hæmmeren panobinostat til behandling af myelom |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20080221126A1 (da) |
| EP (1) | EP1912640B1 (da) |
| JP (2) | JP5665271B2 (da) |
| KR (1) | KR101354237B1 (da) |
| CN (2) | CN104324025A (da) |
| AU (1) | AU2006278718B2 (da) |
| BR (1) | BRPI0614090A2 (da) |
| CA (1) | CA2617274C (da) |
| DK (1) | DK1912640T3 (da) |
| ES (1) | ES2545076T3 (da) |
| HU (1) | HUE028025T2 (da) |
| LT (1) | LTC1912640I2 (da) |
| MX (1) | MX2008001610A (da) |
| PL (1) | PL1912640T3 (da) |
| PT (1) | PT1912640E (da) |
| RU (1) | RU2420279C3 (da) |
| SI (1) | SI1912640T1 (da) |
| WO (1) | WO2007019116A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080221126A1 (en) * | 2005-08-03 | 2008-09-11 | Atadja Peter W | Use of Hdac Inhibitors for the Treatment of Myeloma |
| RU2009134223A (ru) * | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
| WO2008150782A1 (en) * | 2007-05-30 | 2008-12-11 | Novartis Ag | Use of hdac inhibitors for the treatment of bone destruction |
| US20120046242A1 (en) * | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
| EP3868377A1 (en) † | 2009-11-13 | 2021-08-25 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| US20130171141A1 (en) * | 2010-09-01 | 2013-07-04 | Novartis Ag | Combination of hdac inhibitors with thrombocytopenia drugs |
| MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
| WO2017077008A1 (en) | 2015-11-03 | 2017-05-11 | Hochschule Darmstadt | Selective hdac8 inhibitors and their uses |
| CN105348169B (zh) * | 2015-11-16 | 2018-03-30 | 青岛大学 | 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用 |
| CN109705057B (zh) * | 2017-10-25 | 2023-05-30 | 成都先导药物开发股份有限公司 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| WO2020018778A1 (en) | 2018-07-18 | 2020-01-23 | Surender Kharbanda | Polymeric nanoparticles comprising salinomycin |
| WO2022251844A1 (en) | 2021-05-25 | 2022-12-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising chemotherapeutic compounds and related methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP2253319A1 (en) * | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
| WO2003048774A1 (en) | 2001-12-07 | 2003-06-12 | Novartis Ag | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| AU2004241729A1 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| CN101856348A (zh) | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | 联合治疗癌症的方法 |
| EP2491926B1 (en) | 2005-03-22 | 2018-05-09 | President and Fellows of Harvard College | Treatment of protein degradation disorders |
| US20080221126A1 (en) * | 2005-08-03 | 2008-09-11 | Atadja Peter W | Use of Hdac Inhibitors for the Treatment of Myeloma |
-
2006
- 2006-08-01 US US11/996,323 patent/US20080221126A1/en not_active Abandoned
- 2006-08-01 AU AU2006278718A patent/AU2006278718B2/en not_active Ceased
- 2006-08-01 DK DK06789025.1T patent/DK1912640T3/da active
- 2006-08-01 KR KR1020087002803A patent/KR101354237B1/ko active Protection Beyond IP Right Term
- 2006-08-01 CA CA2617274A patent/CA2617274C/en active Active
- 2006-08-01 RU RU2008107871A patent/RU2420279C3/ru not_active IP Right Cessation
- 2006-08-01 BR BRPI0614090-4A patent/BRPI0614090A2/pt not_active Application Discontinuation
- 2006-08-01 HU HUE06789025A patent/HUE028025T2/en unknown
- 2006-08-01 JP JP2008525092A patent/JP5665271B2/ja active Active
- 2006-08-01 MX MX2008001610A patent/MX2008001610A/es active IP Right Grant
- 2006-08-01 PL PL06789025T patent/PL1912640T3/pl unknown
- 2006-08-01 PT PT67890251T patent/PT1912640E/pt unknown
- 2006-08-01 SI SI200631952T patent/SI1912640T1/sl unknown
- 2006-08-01 EP EP06789025.1A patent/EP1912640B1/en active Active
- 2006-08-01 ES ES06789025.1T patent/ES2545076T3/es active Active
- 2006-08-01 WO PCT/US2006/029801 patent/WO2007019116A1/en active Application Filing
- 2006-08-01 CN CN201410610419.9A patent/CN104324025A/zh active Pending
- 2006-08-01 CN CNA2006800281244A patent/CN101232880A/zh active Pending
-
2010
- 2010-03-04 US US12/717,373 patent/US8883842B2/en active Active
-
2013
- 2013-04-04 JP JP2013078867A patent/JP5876435B2/ja active Active
-
2016
- 2016-01-22 LT LTPA2016003C patent/LTC1912640I2/lt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080031937A (ko) | 2008-04-11 |
| US8883842B2 (en) | 2014-11-11 |
| RU2420279C2 (ru) | 2011-06-10 |
| LTC1912640I2 (lt) | 2017-09-11 |
| EP1912640B1 (en) | 2015-06-17 |
| JP5876435B2 (ja) | 2016-03-02 |
| CA2617274A1 (en) | 2007-02-15 |
| ES2545076T3 (es) | 2015-09-08 |
| PT1912640E (pt) | 2015-09-22 |
| CA2617274C (en) | 2017-10-10 |
| RU2008107871A (ru) | 2009-09-10 |
| AU2006278718A1 (en) | 2007-02-15 |
| CN104324025A (zh) | 2015-02-04 |
| JP2009503087A (ja) | 2009-01-29 |
| KR101354237B1 (ko) | 2014-01-22 |
| SI1912640T1 (sl) | 2015-10-30 |
| JP5665271B2 (ja) | 2015-02-04 |
| US20100160257A1 (en) | 2010-06-24 |
| EP1912640A1 (en) | 2008-04-23 |
| PL1912640T3 (pl) | 2015-11-30 |
| RU2420279C3 (ru) | 2017-03-14 |
| HUE028025T2 (en) | 2016-11-28 |
| MX2008001610A (es) | 2008-02-19 |
| AU2006278718B2 (en) | 2010-10-07 |
| BRPI0614090A2 (pt) | 2011-03-09 |
| US20080221126A1 (en) | 2008-09-11 |
| CN101232880A (zh) | 2008-07-30 |
| JP2013173757A (ja) | 2013-09-05 |
| WO2007019116A1 (en) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1912640T3 (da) | Anvendelse af hdac-hæmmeren panobinostat til behandling af myelom | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| ES2863996T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| US20220313702A1 (en) | Oxathiazin compounds for inhibiting gapdh | |
| AU2010235917A1 (en) | Combination of organic compounds | |
| JP2016128437A (ja) | Ｈｄａｃ阻害剤と血小板減少症薬との組合せ | |
| US20220409582A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
| TW202341990A (zh) | 聯合療法 | |
| AU2020220197A1 (en) | Combination therapy using belinostat and pralatrexate to treat lymphoma | |
| US20220323452A1 (en) | Methods and compositions for inhibiting gapdh | |
| US11433069B2 (en) | Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and JAK1/2 inhibitors | |
| WO2021048418A1 (en) | Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma | |
| AU2015205822A1 (en) | Combination of HDAC inhibitors with thrombocytopenia drugs |